Aktis Oncology (AKTS) Stock Price, News & Analysis

Company Overview

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company's activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones. Aktis engages in translational research to move promising molecules from discovery into human testing, and may pursue collaborations or other corporate-development strategies common in the biopharmaceutical sector to accelerate program advancement and broaden development capabilities.

As a publicly traded company on the Nasdaq, Aktis Oncology operates within the broader biotech and pharmaceutical ecosystem and reports progress on its programs to investors and other stakeholders. Public disclosures and regulatory filings are the primary sources for up-to-date information on the company’s pipeline, development timelines and corporate plans. I couldn't find sufficiently detailed, independently verifiable public information on specific products, leadership or geographic headquarters to include here without risking inaccuracy.

Key Stats

• Today's Range: $23.44 to $24.75
• 50-Day Range: $19.46 to $32.36
• 52-Week Range: $14.72 to $34.19
• Volume: 178,420 shs
• Average Volume: 335,150 shs
• Market Capitalization: $1.29 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.00
• Consensus Rating: Moderate Buy

Aktis Oncology Stock Analysis - MarketRank™

Aktis Oncology scored higher than 58% of companies evaluated by MarketBeat, and ranked 471st out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Aktis Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 1 strong buy rating, 8 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Aktis Oncology has a consensus price target of $35.00, representing about 48.9% upside from its current price of $23.51.

Amount of Analyst Coverage

Aktis Oncology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Aktis Oncology are expected to decrease in the coming year, from ($1.76) to ($2.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aktis Oncology is -28.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aktis Oncology is -28.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aktis Oncology has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.50% of the float of Aktis Oncology has been sold short.

Short Interest Ratio / Days to Cover

Aktis Oncology has a short interest ratio ("days to cover") of 12.84, which indicates bearish sentiment.

Change versus previous month

Short interest in Aktis Oncology has recently decreased by 7.24%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aktis Oncology does not currently pay a dividend.

Dividend Growth

Aktis Oncology does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.13

News Sentiment

Aktis Oncology has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Aktis Oncology this week, compared to 5 articles on an average week.

Search Interest

Only 2 people have searched for AKTS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Aktis Oncology to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Aktis Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $119,263.00 in company stock.

Percentage Held by Insiders

3.30% of the stock of Aktis Oncology is held by insiders.

Percentage Held by Institutions

28.84% of the stock of Aktis Oncology is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 8/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AKTS
• CIK: 2035832
• Web: www.aktisoncology.com
• Phone: (978) 237-4380
• Fax: N/A
• Employees: 76
• Year Founded: 2020

Price Target and Rating

• Average Price Target for Aktis Oncology: $35.00
• High Price Target: $40.00
• Low Price Target: $31.00
• Potential Upside/Downside: +44.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.33
• Quick Ratio: 16.33

Sales & Book Value

• Annual Sales: $6.50 million
• Price / Sales: 199.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.08 per share
• Price / Book: 2.67

Miscellaneous

• Outstanding Shares: 53,400,000
• Free Float: 51,643,000
• Market Cap: $1.29 billion
• Optionable: Optionable
• Beta: N/A